Definium Therapeutics, Inc.
A clinical-stage biopharmaceutical company in New York City developing psychedelic-based medicines for psychiatric and neurological disorders. Founded in 2019 as MindMed, a startup exploring LSD and other psychedelics as therapies, it rebranded to Definium Therapeutics in 2026. Its lead program, DT120, is an orally disintegrating tablet of lysergide (LSD) designed to dissolve on the tongue.
Granted 1.04M · Bought 1.0K · Sold 250.7K
Granted 365.0K · Sold 46.0K
Sold 40.7K
Granted 337.5K · Sold 91.1K
Granted 50.0K
Sold 11.4K
Granted 212.5K · Sold 3.0K
Granted 177.5K · Sold 2.9K
Granted 50.0K · Sold 7.0K
Granted 4.7K
Granted 4.7K
Granted 4.7K
Granted 4.7K · Bought 6.0K
Granted 4.7K
Granted 3.6K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Barrow RobertChief Executive Officer, Director · 18 transactions | +76.2% | 1.10M | 1.04M | 1.0K | 250.7K |
| Karlin DanielChief Medical Officer · 9 transactions | — | 503.3K | 365.0K | — | 46.0K |
| Karlin DanChief Medical Officer · 7 transactions | -10.7% | 338.0Kas of Dec 2024 | — | — | 40.7K |
| Sullivan MarkChief Legal Officer · 12 transactions | +60.3% | 320.6K | 337.5K | — | 91.1K |
| Halperin Wernli MiriExecutive President · 2 transactions | — | 235.0Kas of Aug 2024 | 50.0K | — | — |
| Greenway Schond L.Chief Financial Officer · 4 transactions | -7.4% | 211.1Kas of Mar 2024 | — | — | 11.4K |
| Roberts BrandiChief Financial Officer · 3 transactions | — | 209.5K | 212.5K | — | 3.0K |
| Wiley Matthew T.Chief Commercial Officer · 3 transactions | — | 174.6K | 177.5K | — | 2.9K |
| Liao CarrieChief Accounting Officer · 4 transactions | +42.2% | 144.9Kas of Mar 2025 | 50.0K | — | 7.0K |
| Bruhn Suzanne LouiseDirector · 1 transaction | +23.8% | 24.3K | 4.7K | — | — |
| Crystal RogerDirector · 1 transaction | +23.8% | 24.3K | 4.7K | — | — |
| Vallone Carol ADirector · 1 transaction | +28.2% | 21.2K | 4.7K | — | — |
| Gryska David WDirector · 3 transactions | +43.7% | 19.9K | 4.7K | 6.0K | — |
| Krebs AndreasDirector · 1 transaction | +30.9% | 19.8K | 4.7K | — | — |
| Adsett RogerDirector · 1 transaction | — | 3.6K | 3.6K | — | — |
Select a row to see that insider’s individual transactions.
Net open-market activity over the last 3 years: -445.9K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.